What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
Where is Alimera Sciences' stock going? Where will Alimera Sciences' stock price be in 2017?
2 brokers have issued 1-year target prices for Alimera Sciences' stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Alimera Sciences' share price to reach $4.00 in the next year.
When will Alimera Sciences announce their earnings?
Alimera Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (1/17/2017)
Cowen and Company analysts commented, "ALIM pre-announced 2Q16 revenue of $9.3-9.5M ahead of our estimate of $7.8M." (7/26/2016)
Who owns Alimera Sciences stock?
Alimera Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Patrick Lee, MD (22.73%), Deerfield Management Co. (9.06%), Stonepine Capital Management LLC (7.12%), Armistice Capital LLC (4.93%), Palo Alto Investors LLC (4.65%) and North Run Capital LP (2.67%). Company insiders that own Alimera Sciences stock include C Daniel Myers, Calvin W Roberts, James E Flynn, Kenneth Green, LP Bavp, Richard S Eiswirth Jr and Richard S Eiswirth, Jr.
Who sold Alimera Sciences stock? Who is selling Alimera Sciences stock?
Alimera Sciences' stock was sold by a variety of institutional investors in the last quarter, including North Run Capital LP. Company insiders that have sold Alimera Sciences stock in the last year include LP Bavp and Richard S Eiswirth Jr.
Who bought Alimera Sciences stock? Who is buying Alimera Sciences stock?
Alimera Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Armistice Capital LLC and Alyeska Investment Group L.P.. Company insiders that have bought Alimera Sciences stock in the last two years include Calvin W Roberts, James E Flynn and Richard S Eiswirth Jr.
How do I buy Alimera Sciences stock?
Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alimera Sciences stock cost?
One share of Alimera Sciences stock can currently be purchased for approximately $1.22.